Explore our core portfolio of customized clinical, analytical, and pharmacological research services engineered for multinational pharmaceutical, dietary supplement, and personal care brand owners.
Deciphering the shifting paradigms of clinical outsourcing: mitigating regulatory friction, batch variation, and clinical attrition in botanical drugs and functional ingredients.
Global pharmaceutical procurers and nutraceutical innovators frequently face erratic clinical outcomes caused by botanical chemotype fluctuations. As an integrated OEM clinical research supplier, MedGence solves this via rigorous geographic, seasonal, and botanical part evaluations, ensuring that baseline actives remain structurally consistent from exploratory Phase I trials through commercial launch.
Whether navigating U.S. FDA Botanical Drug Guidance, EU EMA Herbal Directives, or China NMPA registrations, enterprise buyers require defensible analytical fingerprints and toxicity packages. Our CDMO/CRO umbrella integrates multi-compound HPTLC, HPLC, and GC quantification to deliver complete audit-ready CTD packages that drastically eliminate NDA and IND submission delays.
Contract research frequently stalls at the technology transfer gate when third-party CROs hand off assays to independent factories. MedGence pairs dedicated laboratory discovery teams directly with internally controlled pilot manufacturing and GMP-compliant factories, safeguarding process parameters and proprietary formulas under single-source non-disclosure protocols.
A systematic methodology transitioning complex natural botanicals into reproducible, clinically validated pharmaceuticals and standardized consumer health products.
High-throughput screening of raw plant matrices, identifying marker constituents, and establishing geographical and seasonal potency benchmarks for long-term consistency.
Creation and validation of specific HPLC, HPTLC, and GC chromatographic standards, establishing quantitative assays and identifying adulteration parameters.
Cellular target engagement, GLP-compliant acute (LD50), chronic toxicity, and genotoxicity evaluations demonstrating biosafety margins before human exposure.
Phase I–IV clinical study execution, biomarker-monitored human efficacy trials for dietary supplements, accompanied by commercial-scale finished dosage manufacturing.
Navigating the complex interplay between traditional medicine heritage and modern international pharmacopeias.
Every clinical batch, formulation development program, and pilot assay is insulated under robust intellectual property frameworks. Client data, extract yields, and dosage innovations are retained strictly within sovereign, confidential boundaries.
Our analytical and clinical designs align with USP, EP, CP, and WHO specifications. Chromatographic validation covers heavy metals, pesticide residues, aflatoxins, and residual solvents to eliminate market entry barriers across North America, Europe, and Asia-Pacific.
Finished dosage formulations include oral liquids, microencapsulated powders, solid tablets, enteric capsules, softgels, and instant granules engineered for stable release kinetics and superior consumer sensory acceptance.
Trusted by industry leaders, state research academies, and Tier-3 TCM hospitals worldwide for critical therapeutic validation.
Tongrentang Group
China Resources Sanjiu
Sunflower Pharma
Livzon Pharma Group
Dihon Pharma
Golden Throat Group
Yangtzi River Pharma
Humanwell Healthcare
Shuguang Hospital TCM
Second Xiangya Hospital
Essential guidance for biopharma directors, regulatory leads, and portfolio sourcing managers.
Select specialized research capabilities or initiate an entrusted CDMO program backed by verifiable scientific datasets.
